Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors

NCT05057130 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Osteosarcoma
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Sarcoma
Sarcoma of Bone

Interventions

DRUG: Doxorubicin, Cisplatin, Methotrexate
DRUG: Doxorubicin, Cisplatin

Sponsor

Blokhin's Russian Cancer Research Center